In trading on Wednesday, shares of Xeris Biopharma Holdings Inc (Symbol: XERS) touched a new 52-week high of $3.07/share. That's a 171.68% rise, or $1.94 per share from the 52-week low of $1.13 set back on 03/10/2023. That means at today's intraday high, any investor who purchased XERS stock any time over the past 52 weeks has an unrealized gain, including company insiders.
Over the past six months, insiders have been scooping up shares, and those bets are now paying off handsomely. As summarized by the table below, XERS has seen 3 different instances of insiders buying over the trailing six month period.
| Purchased | Insider | Title | Shares | Price/Share | Value |
|---|---|---|---|---|---|
| 11/14/2023 | Marla Persky | Director | 6,370 | $1.58 | $10,057.59 |
| 11/16/2023 | John P. Schmid | Director | 6,500 | $1.51 | $9,815.00 |
| 11/27/2023 | Jeffrey W. Sherman | Director | 5,400 | $1.87 | $10,098.00 |
The chart below shows where XERS has traded over the past year, with the 50-day and 200-day moving averages included.
In afternoon trading on Wednesday, XERS shares are changing hands at $3.06/share, slightly below the new 52-week high.
Also see:
TBNK Videos BSEP Videos
ETFs Holding FOSL
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
